Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28646112 | 0.93 | USP2 (0.46) | USP2SMN1; SMN2ESR2NR1H2MAPK1 | |
| SCHEMBL15464058 | 0.83 | ESR2 (0.50) | USP2SMN1; SMN2ESR2NR1H2MAPK1 | |
| SCHEMBL28059941 | 0.80 | ESR2 (0.45) | USP2SMN1; SMN2ESR2NR1H2MAPK1 | |
| SCHEMBL14795217 | 0.79 | USP2 (0.51) | USP2SMN1; SMN2ESR2NR1H2MAPK1 | |
| SCHEMBL22720419 | 0.77 | NR1H2 (0.40) | USP2SMN1; SMN2ESR2NR1H2MAPK1 | |
| SCHEMBL2292608 | 0.77 | USP2 (0.52) | USP2SMN1; SMN2ESR2NR1H2MAPK1 | |
| SCHEMBL28471732 | 0.76 | NR1H2 (0.54) | USP2SMN1; SMN2NR1H2HDAC1HPGD | |
| SCHEMBL995131 | 0.76 | USP2 (0.52) | USP2SMN1; SMN2ESR2NR1H2MAPK1 | |
| SCHEMBL17080478 | 0.75 | USP2 (0.50) | USP2SMN1; SMN2ESR2NR1H2MAPK1 | |
| SCHEMBL13801225 | 0.75 | USP2 (0.50) | USP2SMN1; SMN2ESR2NR1H2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| EP-3978490-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-04-06 | — | — | EP | disclosed |
| CN-113423703-A | Nitrogen-containing heterocyclic derivative regulator, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020239077-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, NRAS, GNAQ | USP2 2996/4885SMN1; SMN2 1129/4885ESR2 3986/4885 |
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | KRAS, NRAS, GNAQ | USP2 3732/4885SMN1; SMN2 1123/4885ESR2 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.